1 Testosterone - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

1 Testosterone

The Experts below are selected from a list of 279 Experts worldwide ranked by ideXlab platform

1 Testosterone – Free Register to Access Experts & Abstracts

Martin Miner – One of the best experts on this subject based on the ideXlab platform.

  • Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Postgraduate medicine, 2013
    Co-Authors: Gary Blick, Mohit Khera, Harvey Kushner, Rajib K. Bhattacharya, Martin Miner
    Abstract:

    AbstractBackground: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), Testosterone levels after Testosterone replacement therapy (TRT) in this population have not been reported. Methods: The Testim Registry in the United States (TRiUS) was the first prospective, observational registry of men with hypogonadism who were prescribed TRT. The TRiUS cohorts with (n = 82) and without (n = 767) HTV/AIDS were followed during 12 months of treatment with Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.). Total Testosterone (TT) and free Testosterone levels, symptoms of depression, sexual function, body composition profiles, and prostate-specific antigen levels were evaluated. Results: The HIV/AIDS and non-HIV/AIDS cohorts differed at baseline in age (48.3 vs 52.5 years), TT level (13.0 vs 9.6 nmol/L), duration of hypogonadism (27.1 vs 14.6 months), prior TRT (36.6% vs 22.6%), body mass index (26.5 vs 32.0 kg/m2), and antidepressant (…

  • 12-month observation of Testosterone replacement effectiveness in a general population of men.
    Postgraduate medicine, 2013
    Co-Authors: Martin Miner, Harvey Kushner, Rajib K. Bhattacharya, Gary Blick, Mohit Khera
    Abstract:

    AbstractBackground: Testosterone decline becomes more prevalent as men age and symptomatic Testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding disease management in a typical patient population, including diagnosis, treatment, and outcomes. Materials and Methods: The Testim Registry in the United States (TRiUS) was a prospective, 12-month, observational cohort registry of men prescribed Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.) for the first time; patients previously on other forms of Testosterone replacement therapy (TRT) were eligible to participate in the study as well. The registry recorded total Testosterone (TT) and free Testosterone (FT) levels, prostate-specific antigen (PSA), sexual function, mood/depression, and cardiometabolic and anthropometric criteria before and after TRT. Changes over time were analyzed by analysis of variance, and linear regression and Pears

  • changes in prostate specific antigen in hypogonadal men after 12 months of Testosterone replacement therapy support for the prostate saturation theory
    The Journal of Urology, 2011
    Co-Authors: Mohit Khera, Harvey Kushner, Rajib K. Bhattacharya, Gary Blick, Dat Nguyen, Martin Miner
    Abstract:

    Purpose: We measured prostate specific antiantigen after 12 months of Testosterone replacement therapy in hypogonadal men.Materials and Methods: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on Testosterone replacement therapy (849). Participants were Testim naive, had no prostate cancer and received 5 to 10 gm Testim 1% (Testosterone gel) daily.Results: A total of 451 patients with prostate specific antiantigen and total Testosterone values were divided into group A (197 with total Testosterone less than 250 ng/dl) and group B (254 with total Testosterone 250 ng/dl or greater). The groups differed significantly in free Testosterone and sex hormone-binding globulin, but not in age or prostate specific antiantigen. In group A but not group B prostate specific antiantigen correlated significantly with total Testosterone (r = 0.20, p = 0.005), free Testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. A…

Mohit Khera – One of the best experts on this subject based on the ideXlab platform.

  • Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Postgraduate medicine, 2013
    Co-Authors: Gary Blick, Mohit Khera, Harvey Kushner, Rajib K. Bhattacharya, Martin Miner
    Abstract:

    AbstractBackground: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), Testosterone levels after Testosterone replacement therapy (TRT) in this population have not been reported. Methods: The Testim Registry in the United States (TRiUS) was the first prospective, observational registry of men with hypogonadism who were prescribed TRT. The TRiUS cohorts with (n = 82) and without (n = 767) HTV/AIDS were followed during 12 months of treatment with Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.). Total Testosterone (TT) and free Testosterone levels, symptoms of depression, sexual function, body composition profiles, and prostate-specific antigen levels were evaluated. Results: The HIV/AIDS and non-HIV/AIDS cohorts differed at baseline in age (48.3 vs 52.5 years), TT level (13.0 vs 9.6 nmol/L), duration of hypogonadism (27.1 vs 14.6 months), prior TRT (36.6% vs 22.6%), body mass index (26.5 vs 32.0 kg/m2), and antidepressant (…

  • 12-month observation of Testosterone replacement effectiveness in a general population of men.
    Postgraduate medicine, 2013
    Co-Authors: Martin Miner, Harvey Kushner, Rajib K. Bhattacharya, Gary Blick, Mohit Khera
    Abstract:

    AbstractBackground: Testosterone decline becomes more prevalent as men age and symptomatic Testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding disease management in a typical patient population, including diagnosis, treatment, and outcomes. Materials and Methods: The Testim Registry in the United States (TRiUS) was a prospective, 12-month, observational cohort registry of men prescribed Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.) for the first time; patients previously on other forms of Testosterone replacement therapy (TRT) were eligible to participate in the study as well. The registry recorded total Testosterone (TT) and free Testosterone (FT) levels, prostate-specific antigen (PSA), sexual function, mood/depression, and cardiometabolic and anthropometric criteria before and after TRT. Changes over time were analyzed by analysis of variance, and linear regression and Pears…

  • changes in prostate specific antigen in hypogonadal men after 12 months of Testosterone replacement therapy support for the prostate saturation theory
    The Journal of Urology, 2011
    Co-Authors: Mohit Khera, Harvey Kushner, Rajib K. Bhattacharya, Gary Blick, Dat Nguyen, Martin Miner
    Abstract:

    Purpose: We measured prostate specific antigen after 12 months of Testosterone replacement therapy in hypogonadal men.Materials and Methods: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on Testosterone replacement therapy (849). Participants were Testim naive, had no prostate cancer and received 5 to 10 gm Testim 1% (Testosterone gel) daily.Results: A total of 451 patients with prostate specific antigen and total Testosterone values were divided into group A (197 with total Testosterone less than 250 ng/dl) and group B (254 with total Testosterone 250 ng/dl or greater). The groups differed significantly in free Testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total Testosterone (r = 0.20, p = 0.005), free Testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. A…

Gary Blick – One of the best experts on this subject based on the ideXlab platform.

  • Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Postgraduate medicine, 2013
    Co-Authors: Gary Blick, Mohit Khera, Harvey Kushner, Rajib K. Bhattacharya, Martin Miner
    Abstract:

    AbstractBackground: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), Testosterone levels after Testosterone replacement therapy (TRT) in this population have not been reported. Methods: The Testim Registry in the United States (TRiUS) was the first prospective, observational registry of men with hypogonadism who were prescribed TRT. The TRiUS cohorts with (n = 82) and without (n = 767) HTV/AIDS were followed during 12 months of treatment with Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.). Total Testosterone (TT) and free Testosterone levels, symptoms of depression, sexual function, body composition profiles, and prostate-specific antigen levels were evaluated. Results: The HIV/AIDS and non-HIV/AIDS cohorts differed at baseline in age (48.3 vs 52.5 years), TT level (13.0 vs 9.6 nmol/L), duration of hypogonadism (27.1 vs 14.6 months), prior TRT (36.6% vs 22.6%), body mass index (26.5 vs 32.0 kg/m2), and antidepressant (…

  • 12-month observation of Testosterone replacement effectiveness in a general population of men.
    Postgraduate medicine, 2013
    Co-Authors: Martin Miner, Harvey Kushner, Rajib K. Bhattacharya, Gary Blick, Mohit Khera
    Abstract:

    AbstractBackground: Testosterone decline becomes more prevalent as men age and symptomatic Testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding disease management in a typical patient population, including diagnosis, treatment, and outcomes. Materials and Methods: The Testim Registry in the United States (TRiUS) was a prospective, 12-month, observational cohort registry of men prescribed Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.) for the first time; patients previously on other forms of Testosterone replacement therapy (TRT) were eligible to participate in the study as well. The registry recorded total Testosterone (TT) and free Testosterone (FT) levels, prostate-specific antigen (PSA), sexual function, mood/depression, and cardiometabolic and anthropometric criteria before and after TRT. Changes over time were analyzed by analysis of variance, and linear regression and Pears…

  • changes in prostate specific antigen in hypogonadal men after 12 months of Testosterone replacement therapy support for the prostate saturation theory
    The Journal of Urology, 2011
    Co-Authors: Mohit Khera, Harvey Kushner, Rajib K. Bhattacharya, Gary Blick, Dat Nguyen, Martin Miner
    Abstract:

    Purpose: We measured prostate specific antigen after 12 months of Testosterone replacement therapy in hypogonadal men.Materials and Methods: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on Testosterone replacement therapy (849). Participants were Testim naive, had no prostate cancer and received 5 to 10 gm Testim 1% (Testosterone gel) daily.Results: A total of 451 patients with prostate specific antigen and total Testosterone values were divided into group A (197 with total Testosterone less than 250 ng/dl) and group B (254 with total Testosterone 250 ng/dl or greater). The groups differed significantly in free Testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total Testosterone (r = 0.20, p = 0.005), free Testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. A…

Harvey Kushner – One of the best experts on this subject based on the ideXlab platform.

  • Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
    Postgraduate medicine, 2013
    Co-Authors: Gary Blick, Mohit Khera, Harvey Kushner, Rajib K. Bhattacharya, Martin Miner
    Abstract:

    AbstractBackground: Although hypogonadism is common in men with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), Testosterone levels after Testosterone replacement therapy (TRT) in this population have not been reported. Methods: The Testim Registry in the United States (TRiUS) was the first prospective, observational registry of men with hypogonadism who were prescribed TRT. The TRiUS cohorts with (n = 82) and without (n = 767) HTV/AIDS were followed during 12 months of treatment with Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.). Total Testosterone (TT) and free Testosterone levels, symptoms of depression, sexual function, body composition profiles, and prostate-specific antigen levels were evaluated. Results: The HIV/AIDS and non-HIV/AIDS cohorts differed at baseline in age (48.3 vs 52.5 years), TT level (13.0 vs 9.6 nmol/L), duration of hypogonadism (27.1 vs 14.6 months), prior TRT (36.6% vs 22.6%), body mass index (26.5 vs 32.0 kg/m2), and antidepressant (…

  • 12-month observation of Testosterone replacement effectiveness in a general population of men.
    Postgraduate medicine, 2013
    Co-Authors: Martin Miner, Harvey Kushner, Rajib K. Bhattacharya, Gary Blick, Mohit Khera
    Abstract:

    AbstractBackground: Testosterone decline becomes more prevalent as men age and symptomatic Testosterone deficiency is associated with potentially serious comorbidities. Despite limitations, registries can provide an opportunity to accumulate data regarding disease management in a typical patient population, including diagnosis, treatment, and outcomes. Materials and Methods: The Testim Registry in the United States (TRiUS) was a prospective, 12-month, observational cohort registry of men prescribed Testim® (1% Testosterone gel; Auxilium Pharmaceuticals, Inc.) for the first time; patients previously on other forms of Testosterone replacement therapy (TRT) were eligible to participate in the study as well. The registry recorded total Testosterone (TT) and free Testosterone (FT) levels, prostate-specific antigen (PSA), sexual function, mood/depression, and cardiometabolic and anthropometric criteria before and after TRT. Changes over time were analyzed by analysis of variance, and linear regression and Pears…

  • changes in prostate specific antigen in hypogonadal men after 12 months of Testosterone replacement therapy support for the prostate saturation theory
    The Journal of Urology, 2011
    Co-Authors: Mohit Khera, Harvey Kushner, Rajib K. Bhattacharya, Gary Blick, Dat Nguyen, Martin Miner
    Abstract:

    Purpose: We measured prostate specific antigen after 12 months of Testosterone replacement therapy in hypogonadal men.Materials and Methods: Data were collected from the TRiUS (Testim® Registry in the United States), an observational registry of hypogonadal men on Testosterone replacement therapy (849). Participants were Testim naive, had no prostate cancer and received 5 to 10 gm Testim 1% (Testosterone gel) daily.Results: A total of 451 patients with prostate specific antigen and total Testosterone values were divided into group A (197 with total Testosterone less than 250 ng/dl) and group B (254 with total Testosterone 250 ng/dl or greater). The groups differed significantly in free Testosterone and sex hormone-binding globulin, but not in age or prostate specific antigen. In group A but not group B prostate specific antigen correlated significantly with total Testosterone (r = 0.20, p = 0.005), free Testosterone (r = 0.22, p = 0.03) and sex hormone-binding globulin (r = 0.59, p = 0.002) at baseline. A…

Katarzyna Tyszczuk – One of the best experts on this subject based on the ideXlab platform.